Advanced Magnetics gets buy rating from Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated Advanced Magnetics, Inc. at a buy. Walsh believes it is highly likely that ferumoxytol phase 3 CKD efficacy and safety data will be announced at the American Society of Nephrology meeting in November, giving the company two potential drivers in the fourth quarter. of the Cambridge, Mass.-based pharmaceutical products company were up 83 cents, or 2.39%, at $35.63. (Nasdaq: AMAG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.